Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski, recently published a series of three papers on investigating the risk of acute liver failure (ALF) following systemic administration of quinolones, based on a synthesis of evidence from available clinical trials, the US FDA Adverse Event Reporting System (FAERS), and a large US database of electronic health records (EHR).
Although clinical trials provided little evidence of an increased risk, there were reports in FAERS of quinolone-linked ALF cases. Although the primary EHR analysis did not reveal an overall association between quinolones as a class and ALF risk, a possible risk was identified among those with no or few comorbidities, those ≤ 60 years of age, women, men, African Americans, and Caucasians.
The authors noted that elevated risks seen in some subgroups warrant further investigation.
Posted in RSI News
More RSI News
Dr. Mattison chairs NAM report
Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics. Over the past half-century – with the…
Read News ItemCountry Foods Forum
Leading up to February 11 and 12, 2020, Risk Sciences International had the privilege of assisting Health Canada in its organization of the Country Foods…
Read News ItemWorkshop on Evidence Integration December 5-6, 2019
Risk Sciences International is organizing a two day Workshop on Evidence Integration in support of human health risk assessment in collaboration with the McLaughlin Centre…
Read News ItemRSI wins 2019 Consulting Engineers of Ontario Award of Merit
Risk Sciences International (RSI), as members of a consulting team with Stantec, along with the Ontario First Nations Technical Services Corporation (OFNTSC), has won an Award of Merit from the…
Read News Item